U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07703566) titled 'CPAP for Hypoxemic Acute Chest Syndrome in Sickle Cell Disease' on July 08.
Brief Summary: Sickle cell disease (SCD) is a severe hemoglobinopathy, considered the first monogenic disease in the world. Acute chest syndrome (ACS), one of the most frequent and serious complications of SCD, is defined by the association of fever and/or acute respiratory symptoms with a new pulmonary infiltrate on chest imaging. ACS is characterized by lung consolidation, severe pulmonary vascular dysfunction, with potential role for regional alveolar hypoxia. Therefore, improving alveolar oxygenation and limiting lung consolidation are key objectives of ...